Clindamycin is a semisynthetic lincosamide antibiotic that has largely replaced lincomycin due to an improved side effect profile. Clindamycin inhibits bacterial protein synthesis by binding to bacterial 50S ribosomal subunits. It may be bacteriostatic or bactericidal depending on the organism and drug concentration.
For the treatment of serious infections caused by susceptible anaerobic bacteria, including Bacteroides spp., Peptostreptococcus, anaerobic streptococci, Clostridium spp., and microaerophilic streptococci.
May be useful in polymicrobic infections such as intra-abdominal or pelvic infections, osteomyelitis, diabetic foot ulcers, aspiration pneumonia and dental infections. May also be used to treat MSSA and respiratory infections caused by S. pneumoniae and S. pyogenes in patients who are intolerant to other indicated antibiotics or who are infected with resistant organism.
May be used vaginally to treat vaginosis caused by Gardnerella vaginosa. Clindamycin reduces the toxin producing effects of S. aureus and S. pyogenes and as such, may be particularly useful for treating necrotizing fasciitis. May be used topically to treat acne.
Clindamycin is an antibiotic, similar to and a derivative of lincomycin. Clindamycin can be used in topical or systemic treatment. It is effective as an anti-anaerobic antibiotic and antiprotozoal.
Associated Conditions: Abscess, Intra-Abdominal, Acne Vulgaris, Anthrax, Babesiosis, Bacterial Infections, Bacterial Vaginosis (BV), Bloodstream Infections, Colitis, Community Acquired Pneumonia (CAP), Empyema, Endometritis, Infected animal bite, Infective Endocarditis, Intra-Abdominal Infections, Lower Respiratory Tract Infection (LRTI), Lung Abscess, MRSA Infection, Osteomyelitis, Otitis Media (OM), Pelvic cellulitis, Peritonitis, Plasmodium Infections, Pneumonia, Bacterial, Pneumonia, Pneumocystis, Pneumonitis, Respiratory Tract Infections (RTI), Skin and Subcutaneous Tissue Bacterial Infections, Streptococcal Pharyngitis, Toxoplasma gondii encephalitis, Tubo-ovarian abscess, Bacterial rhinosinusitis.
Systemic/vaginal clindamycin inhibits protein synthesis of bacteria by binding to the 50S ribosomal subunits of the bacteria.
Specifically, it binds primarily to the 23s RNA subunit. Topical clindamycin reduces free fatty acid concentrations on the skin and suppresses the growth of Propionibacterium acnes (Corynebacterium acnes) , an anaerobe found in sebaceous glands and follicles.
Metabolism: Hepatic
Absorption: Rapidly absorbed after oral administration with peak serum concentrations observed after about 45 minutes. Absorption of an oral dose is virtually complete (90%) and the concomitant intake of food does not appreciably modify the serum concentrations; serum levels have been uniform and predictable from person to person and dose to dose. Clindamycin does not penetrate the blood brain barrier.
Route of elimination: Approximately 10% of the bioactivity is excreted in the urine and 3.6% in the feces; the remainder is excreted as bioinactive metabolites.
Half life: 2.4 hours
Affected organisms: Enteric bacteria and other eubacteria.
All medicines may cause side effects, but many people have no, or minor, side effects.Some medical conditions may interact with Clindamycin.
Tell your doctor or pharmacist if you have any medical conditions.
Common clindamycin side effects may include: nausea, vomiting, stomach pain, mild skin rash or vaginal itching or discharge.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider.
